<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005994</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067996</org_study_id>
    <secondary_id>URCC-3996</secondary_id>
    <secondary_id>NCI-P00-0160</secondary_id>
    <nct_id>NCT00005994</nct_id>
  </id_info>
  <brief_title>Patient Education in Preventing Nausea and Vomiting in Cancer Patients Receiving Chemotherapy</brief_title>
  <official_title>Patient Information and Antiemetic Drug Efficacy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rochester</source>
  <brief_summary>
    <textblock>
      RATIONALE: Patient education may improve the effectiveness of ondansetron in preventing&#xD;
      nausea and vomiting in patients receiving chemotherapy.&#xD;
&#xD;
      PURPOSE: This randomized clinical trial is studying how well patient education works in&#xD;
      preventing nausea and vomiting in cancer patients receiving chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine whether an educational intervention to enhance the effectiveness of&#xD;
      ondansetron can prevent acute postchemotherapy nausea and emesis in cancer patients. II.&#xD;
      Assess any potential effectiveness of the intervention on delayed postchemotherapy nausea and&#xD;
      emesis in these patients. III. Examine the effect of the intervention on patient&#xD;
      expectations.&#xD;
&#xD;
      OUTLINE: This is a randomized, double blind, multicenter study. Patients are stratified by&#xD;
      center and chemotherapy agent (cisplatin vs carboplatin vs doxorubicin). Patients are&#xD;
      randomized to one of two treatment arms. Arm I: Patients receive standard educational&#xD;
      materials. Arm II: Patients receive specific intervention material in addition to standard&#xD;
      educational materials. Patients then complete a patient information questionnaire. Patients&#xD;
      receive ondansetron orally or IV over 10-15 minutes in addition to the first 2 courses of&#xD;
      chemotherapy. Patients complete a nausea and emesis questionnaire after each of their first 2&#xD;
      chemotherapy treatments.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 300 patients (150 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2000</start_date>
  <completion_date type="Actual">July 2001</completion_date>
  <primary_completion_date type="Actual">July 2001</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
  </study_design_info>
  <condition>Nausea and Vomiting</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ondansetron</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Chemotherapy naive with diagnosis of any cancer scheduled to&#xD;
        receive chemotherapy containing cisplatin, carboplatin, or doxorubicin&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Life&#xD;
        expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not&#xD;
        specified&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary R. Morrow, PhD, MS</last_name>
    <role>Study Chair</role>
    <affiliation>James P. Wilmot Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C.</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Southeast Cancer Control Consortium</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27104-4241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>June 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2004</study_first_posted>
  <last_update_submitted>March 4, 2013</last_update_submitted>
  <last_update_submitted_qc>March 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Gary Morrow</investigator_full_name>
    <investigator_title>Director, URCC CCOP Research Base</investigator_title>
  </responsible_party>
  <keyword>nausea and vomiting</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

